European Haematology Association’s 16th Congress
Last week, haematologists, oncologists and clinicians gathered in London for the European Haematology Association’s (EHA) 16th Congress. At this year’s meeting, in addition to the usual clinical data presentations, patient advocates were given a platform to share their perspective on the treatment and management of haematologic cancers.
The patient advocate session—chaired by Jan Geissler of the CML Advocates Network and Jana Pelouchová of the European Cancer Patient Coalition—provided an opportunity to discuss medication adherence from various stakeholder perspectives, which included:
- Dr. David Marin, of the Imperial College London, presented the results of an adherence trial that measured patient non-adherence.
- Professor Dr. Rudolf Schoberberger, of the Medical University of Vienna, discussed the impact of drug packaging on adherence to therapy.
- Giora Sharf, of the Israeli CML Patients’ Organisation and CML Advocates Network, shared the patient’s perspective on reasons for non-adherence. Giora highlighted the advocates’ role in working with patients to better understand barriers to non-adherence and provided learnings from a recent patient adherence survey pilot.
Judging by the strong turn-out of medical professionals— the room was at capacity and an overflow area was needed— the Patient Advocacy Session was a success! The patient-advocate perspective was well received, appreciated and respected, and in all likelihood there will be a continued role for advocates at future EHA congresses.